Oral Presentation : RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results